Article
VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.
Thrombosis and haemostasis - 1 Jan 2016
Ferroni Patrizia, Palmirotta Raffaele, Riondino Silvia, De Marchis Maria Laura, Nardecchia Antonella, Formica Vincenzo, Guadagni Fiorella, Roselli Mario
Abstract excerpt
Among the possible genetic contributors to cancer-related venous thromboembolism (VTE), vascular endothelial growth factor (VEGFA) could play an important role, as an imbalance of the VEGFA system (either disease-related or drug-induced) may result in a disturbance of vascular homeostasis. Thus,...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Bevacizumab
- Disease-Free Survival
- Female
- Gene Frequency
- Genetic Association Studies
- Genetic Predisposition to Disease
- Haplotypes
- Humans
- Male
- Middle Aged
- Neoplasms
- Phenotype
- Polymorphism, Single Nucleotide
- Promoter Regions, Genetic